<DOC>
	<DOCNO>NCT00951665</DOCNO>
	<brief_summary>This Phase Ib-IIa , multi-institutional , open-label , dose-escalation study design evaluate safety , tolerability , pharmacokinetics feasibility trastuzumab emtansine ( T-DM1 ) administer intravenous ( IV ) infusion combination paclitaxel ( pertuzumab , applicable ) patient human epidermal growth factor receptor 2-positive ( HER2-positive ) , locally advanced metastatic breast cancer .</brief_summary>
	<brief_title>A Study Trastuzumab Emtansine , Paclitaxel , Pertuzumab Patients With HER2-Positive , Locally Advanced Metastatic Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Maytansine</mesh_term>
	<mesh_term>Ado-trastuzumab emtansine</mesh_term>
	<mesh_term>Pertuzumab</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>Histologically document HER2positive locally advance metastatic breast cancer Tumor tissue block 1520 unstained tissue slide confirmatory central laboratory HER2 status test exploratory assessment Prior trastuzumab line therapy ( Phase Ib patient ) No prior TDM1 pertuzumab therapy Measurable evaluable disease Cardiac ejection fraction &gt; =50 % either echocardiogram multigated acquisition scan Life expectancy &gt; = 90 day assess investigator Fewer 21 day since last antitumor therapy , include chemotherapy , biologic , experimental , immune , hormonal radiotherapy treatment breast cancer , follow exception : hormonereplacement therapy oral contraceptive allow ; palliative radiation therapy involve &lt; =25 % marrowbearing bone allow complete within &gt; = 14 day prior first study treatment History intolerance hypersensitivity trastuzumab and/or adverse event related trastuzumab , murine protein , excipients result trastuzumab permanently discontinue Peripheral neuropathy Grade &gt; = 2 per NCI CTCAE , Version 3.0 , time , within 3 week prior , first study therapy ( Phase Ib patient ) Peripheral neuropathy Grade &gt; /=1 per NCI CTCAE , Version 3.0 , time , within 3 week prior , first study therapy ( Phase IIa patient ) History exposure follow cumulative dos anthracyclines : Doxorubicin &gt; 500 mg/m^2 ; Liposomal doxorubicin &gt; 900 mg/m^2 ; Epirubicin &gt; 720 mg/m^2 History clinically significant cardiac dysfunction Brain metastasis untreated , progressive , required type therapy ( include radiation , surgery , steroid ) control symptom brain metastasis within 60 day prior first study treatment . History malignancy within last 5 year , except appropriately treat carcinoma situ cervix , basal cell carcinoma , synchronous subsequent HER2positive breast cancer malignancy similar expect curative outcome</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Trastuzumab DM1 ( T-DM1 )</keyword>
	<keyword>Trastuzumab emtansine</keyword>
	<keyword>Armed Herceptin</keyword>
	<keyword>HER2</keyword>
	<keyword>HER2+</keyword>
	<keyword>HER2 Positive Breast Cancer</keyword>
</DOC>